Treatment of Chronic Spontaneous Urticaria

被引:81
作者
Kaplan, Allen P. [1 ]
机构
[1] Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Med, Charleston, SC 29425 USA
关键词
Urticaria; anti IgE receptor; antihistamine; cyclosporine; omalizumab; CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; CHRONIC AUTOIMMUNE URTICARIA; AFFINITY IGE RECEPTOR; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; HISTAMINE-RELEASE; ANTI-IGE; DOSE OMALIZUMAB; COLD URTICARIA;
D O I
10.4168/aair.2012.4.6.326
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Chronic spontaneous urticaria is defined as persistent symptoms of urticaria for 6 weeks or more. It is associated with autoimmunity in approximately 45 percent of patients. Therapy is often difficult however the initial approach should employ high-dose non-sedating antihistamines; 4-6 tablets/day may be necessary. It has been shown that the response to 4 tablets/day exceeds 3, and exceeds 2, which exceeds 1. However the dose that corresponds to the maximal dose of first generation antihistamines (hydroxyzine, diphenhydramine) used previously, is 6/day. Yet over half the patients are refractory to antihistamines and other agents should be tried next. Whereas current guidelines (published) often add leukotriene antagonists and/or H-2 receptor antogonists next, these are of little utility. Likewise drugs effective for urticarial vasculitis (colchicine, dapsone, sulfasalazine, hydroxychloroquine) are effective in a small percentage of patients and no study suggests that the response rate of any of them exceeds the 30% placebo responses seen in most double-blind, placebo controlled studies. The drugs that are effective for antihistamine-resistant chronic spontaneous urticaria are corticosteroids, cyclosporine, and Omalizumab. Use of steroids is limited by toxicity. If used at all, a dose of no more than 10 mg/day should be employed with a weekly reduction of 1 mg. The response rates to cyclosporine and Omalizumab are each close to 75%. Cyclosporine can be used effectively if care is taken to monitor blood pressure, urine protein, blood urea nitrogen, and creatinine, every 6 weeks. Omalizumab has the best profile in terms of efficacy/toxicity and, once approved by federal agencies for use in chronic spontaneous urticaria, a dramatic change in the treatment paradigm, whether associated with autoimmunity or not, is predicted. A phase 3 trial is currently in place. Refractoriness to both Omalizumab and cyclosporine is expected to be less than 5 percent of patients. Other agents, can then be tried.
引用
收藏
页码:326 / 331
页数:6
相关论文
共 54 条
[1]   Comparison of the in vivo autologous skin test with in vitro diagnostic tests for diagnosis of chronic autoimmune urticaria [J].
Altrich, Michelle L. ;
Halsey, John F. ;
Altman, Leonard C. .
ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (01) :28-34
[2]   Severe chronic urticaria is associated with elevated plasma levels of D-dimer [J].
Asero, R. ;
Tedeschi, A. ;
Riboldi, P. ;
Griffini, S. ;
Bonanni, E. ;
Cugno, M. .
ALLERGY, 2008, 63 (02) :176-180
[3]   Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria [J].
Asero, Riccardo ;
Tedeschi, Alberto ;
Coppola, Raffaella ;
Griffini, Samantha ;
Paparella, Paolo ;
Riboldi, Piersandro ;
Marzano, Angelo V. ;
Fanoni, Daniele ;
Cugno, Massimo .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (03) :705-710
[4]   Risk of first-generation H1-antihistamines: a GA2LEN position paper [J].
Church, M. K. ;
Maurer, M. ;
Simons, F. E. R. ;
Bindslev-Jensen, C. ;
van Cauwenberge, P. ;
Bousquet, J. ;
Holgate, S. T. ;
Zuberbier, T. .
ALLERGY, 2010, 65 (04) :459-466
[5]   Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria [J].
Di Lorenzo, G ;
Pacor, ML ;
Mansueto, P ;
Pellitteri, ME ;
Lo Bianco, C ;
Ditta, V ;
Martinelli, N ;
Rini, GB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (03) :619-625
[6]   Autoantibodies to the high-affinity IgE receptor in children with chronic urticaria [J].
Du Toit, G ;
Prescott, R ;
Lawrence, P ;
Johar, A ;
Brown, G ;
Weinberg, EG ;
Motala, C ;
Potter, PC .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 96 (02) :341-344
[7]   Levocetirizine: The latest treatment option for allergic rhinitis and chronic idiopathic urticaria [J].
DuBuske, Lawrence M. .
ALLERGY AND ASTHMA PROCEEDINGS, 2007, 28 (06) :724-734
[8]   Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies [J].
Eckman, John A. ;
Hamilton, Robert G. ;
Gober, Laura M. ;
Sterba, Patricia M. ;
Saini, Sarbjit S. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (08) :1956-1963
[9]   STUDIES OF THE CELLULAR INFILTRATE OF CHRONIC IDIOPATHIC URTICARIA - PROMINENCE OF LYMPHOCYTES-T, MONOCYTES, AND MAST-CELLS [J].
ELIAS, J ;
BOSS, E ;
KAPLAN, AP .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1986, 78 (05) :914-918
[10]   Comparative studies of functional and binding assays for IgG anti-FcεRIα (α-subunit) in chronic urticaria [J].
Ferrer, M ;
Kinét, JP ;
Kaplan, AP .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (05) :672-676